Recent Updates
Recently added Catalysts

Nurofen for Children

Phase 1

Healthy | Small molecule | Other |Ligand Pharmaceuticals Incorporated|Last Updated: Nov 1, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Clinical trial landscape

Nurofen for Children · 1 trial · 1 indication

Phase 1 1
NCT03561558Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting ConditionsHealthy
COMPLETED30 Analytics
PHASE1COMPLETED
Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting Conditions
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Primary pharmacokinetic parameter for S-enantiomer of ibuprofen
8 days

Peak Plasma Concentration (Cmax)

Secondary Endpoints

Safety and tolerability of the investigational products (testing and reference)
22 days
Secondary pharmacokinetic parameter for S-enantiomer of ibuprofen
8 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
Ibuprofen D, oral suspensionEXPERIMENTALIbuprofen oral suspension, 200 mg/ 5 ml is the test product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (5 ml containing 200 mg of ibuprofen) of suspension.
Nurofen® for Children, oral suspensionACTIVE_COMPARATORNurofen® for Children oral suspension, 100 mg/ 5 ml is the reference product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (10 ml containing 200 mg of ibuprofen) of suspension.

Interventions

NameTypeDescription
Ibuprofen DDRUGIbuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
Nurofen® for ChildrenDRUGNurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy adult human subjects, aged between 18 to 45 years. 2. Subjects with Body Mass Index (BMI) 18.5 to 30 kg/m2. 3. Female subjects with a negative pregnancy test. 4. Non-lactating females. 5. If subject is a female and is of child bearing potential, she should be practici...

Countries:Russia
Unlock Eligibility Criteria

Frequently asked questions about Nurofen for Children

What is Nurofen for Children used for?

Nurofen for Children is an oral suspension of ibuprofen being studied in healthy volunteers. It is a small molecule drug developed by Ligand Pharmaceuticals Incorporated (LGND). The drug is currently in Phase 1 clinical development.

Who makes Nurofen for Children?

Nurofen for Children is being developed by Ligand Pharmaceuticals Incorporated, which trades under the ticker LGND. The drug is a small molecule oral suspension of ibuprofen.

What phase is Nurofen for Children in?

Nurofen for Children is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.

What clinical trials is Nurofen for Children in?

Nurofen for Children has one completed clinical trial, NCT03561558, a Phase 1 bioequivalence study in healthy volunteers under fasting conditions. The study enrolled 30 participants in Russia and was active-controlled.

Is Nurofen for Children the same as ibuprofen?

Nurofen for Children is an oral suspension containing ibuprofen, specifically 100 mg/5 ml. It is being studied for bioequivalence to a reference ibuprofen oral suspension of 200 mg/5 ml.